PhageLab, a Santiago, Chile-based biotechnology company developing bacteriophage-based applications, raised $11M in funding.
Backers included Nazca, Collaborative Fund, Water Lemon Ventures and individual investor Kevin Efrusy.
The company intends to use the funds to advance its pipeline of phage-based solutions and establish a commercial position in Brazil, its main target market, and expand its technology into the US.
Led by CEO Hans Pieringer, PhageLab is a biotechnology company that develops precision bacteriophage treatments to reduce the overuse of antibiotics to control bacteria in breeding processes in the livestock industry. Founded in 2010, the company has developed a microbial bioinformatics platform designed for the search and development of bacteriophage-based treatments. The platform employs AI to generate “customized cocktails,” that can effectively manage pathogenic bacteria in the livestock industry and reduce antibiotic dependence. The training dataset for this platform is based on more than a decade of experimentation data and tested phage repositories, to create one of the world’s largest industrial bacterial databases. PhageLab uses this library to create custom solutions in 45 days, that is safe and effective for use to eliminate livestock bacteria.
The company has offices in Spain and Brazil.
FinSMEs
24/01/2024